Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication

Gene

Volumn 255, Issue 2, 2000, Pages 235-244

  Konopka, Krystyna ^a   Lee, Nan Sook ^b   Rossi, John ^b   Düzgüneş, Nejat ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Fugene; Gene therapy; Human immunodeficiency virus; Lipofectin; Transfection

Indexed keywords

APTAMER; PLASMID DNA; RIBOZYME; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA RESPONSIVE ELEMENT; GENE CONSTRUCT; GENE EXPRESSION; GENE TRANSFER; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; ROUS SARCOMA ONCOVIRUS; TECHNIQUE; TRANSLATION REGULATION; VIRUS REPLICATION; VIRUS VECTOR;

ANTI-HIV AGENTS; BETA-GALACTOSIDASE; CELL LINE; CYTOMEGALOVIRUS; DNA, RECOMBINANT; GENE EXPRESSION REGULATION; GENE PRODUCTS, ENV; GENE PRODUCTS, REV; HELA CELLS; HIV CORE PROTEIN P24; HIV-1; HUMAN; LUCIFERASE; OLIGONUCLEOTIDES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA, CATALYTIC; SIMIAN VIRUS 40; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSFECTION; VIRUS REPLICATION;

EID: 0034687063     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(00)00334-6     Document Type: Article

References (30)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
2. Adam G.I.R., Miller S.J., Ulleras E., Franklin G.C. Cell-type-specific modulation of PDGF-B regulatory elements via viral enhancer competition: a caveat for the use of reference plasmids in transient transfection assays. Gene. 178:1996;25-29.
3. Bertrand E., Castanotto D., Zhou C., Carbonnelle C., Lee N.S., Good P., Chatterjee S., Grange T., Pictet R., Kohn D., Engelke D., Rossi J.J. The expression cassette determined the functional activity of ribozyme in mammalian cells by controlling their intracellular localization. RNA. 3:1997;75-88.
4. Boshart M., Weber F., Jahn G., Dorsch Häsler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 41:1985;521-530.
5. Clark P.R., Hersh E.M. Cationic lipid-mediated gene transfer: current concepts. Curr. Opin. Mol. Therapeut. 1:1999;158-176.
6. Doll R.F., Crandal J.E., Dyaer C.A., Aucoin J.M., Smith F.I. Comparison of promoter strength on gene delivery into mammalian brain cells using AAV vectors. Gene Ther. 3:1996;437-447.
7. Fisher A.G., Collatti E., Ratner L., Gallo R.C., Wong-Staal F. A molecular clone of HTLV-III with biological activity. Nature. 316:1985;262-265.
8. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS. 6:1992;347-363.
9. Gervaix A., Li X., Kraus G., Wong-Staal F. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol. 71:1997;3048-3053.
10. Good P.D., Krokos A.J., Li S.X.L., Bertrand E., Lee N.S., Giver L., Ellington A., Zaia J.A., Rossi J.J., Engelke D.R. Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4:1997;45-54.
11. Hamouda T., McPhee R., Hsia S.-C., Read G.S., Holland T.C., King S.R. Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. J. Virol. 71:1997;5521-5527.
12. Jones K.A., Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717-743.
13. Jones K.A., Luciw P.A., Duchange N. Structural arrangements of transcription control domains within the 5′-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes Dev. 2:1988;1101-1114.
14. Kohn D.B., Sarver N. Gene therapy for HIV-1 infection. Adv. Exp. Med. Biol. 394:1996;421-428.
15. Konopka K., Pretzer E., Felgner P.L., Düzgüneş N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta. 1312:1996;186-196.
16. Konopka K., Düzgüneş N., Rossi J.J., Lee N.S. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. J. Drug Target. 5:1998;247-259.
17. Konopka K., Lee N.S., Rossi J.J., Düzgünes N. Rev-binding Aptamer and CMV promoter act as decoys to inhibit HIV replication. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, Abstr. 938. 1999;320.
18. Lasic D.D., Templeton N.S. Liposomes in gene therapy. Adv. Drug Deliv. Rev. 20:1996;221-266.
19. Lee S.-W., Gallardo H.F., Gilboa E., Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy comprised of the 13-nucleotide minimal Rev-binding domain. J. Virol. 68:1994;8254-8264.
20. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47:1986;333-348.
21. Miyoshi H., Blömer U., Takahashi M., Gage F.H., Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72:1998;8150-8157.
22. Muotri A.R., da Veiga Pereira L., dos Reis Vasques L., Menck C.F.M. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene. 237:1999;303-310.
23. Pereira L.A., Bently K., Peeters A., Churchill M.J., Deacon N.J. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 28:2000;663-668.
24. Roebuck K.A., Saifuddin M. Regulation of HIV-1 transcription. Gene Expr. 8:1999;67-84.
25. Rossi J.J., Sarver N. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. Adv. Exp. Med. Biol. 312:1992;95-109.
26. Subramanian T., Chinnadurai G. A high-level expression vector for human cells. Gene. 120:1992;287-289.
27. Treco D.A., Selden R.F. Non-viral gene therapy. Mol. Med. Today. 1:1995;314-321.
28. Tuerk C., MacDougal-Waugh S. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene. 137:1993;33-39.
29. Yamada O., Kraus G., Luznik L., Yu M., Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Virol. 70:1996;1596-1601.
30. Yamamoto R., Koseki S., Ohkawa J., Murakami K., Nishikawa S., Taira K., Kumar P.K.R. Inhibition of transcription by the TAR RNA of HIV-1 in a nuclear extract of HeLa cells. Nucleic Acids Res. 25:1997;3445-3450.